The mission of biopharma companies to bring effective new therapies to patients to solve unmet medical needs has become much harder these days. Not only has the cost to accomplish those goals jumped significantly, but the prices being set – in large part to recover the R&D investments – are being questioned by politicos, regulators and patients alike who view some of the price points as unjustifiable. Read More
At a workshop sponsored by the Duke-Margolis Center for Health Policy last week, representatives from the FDA, academia, industry and patient groups sat down to discuss the potential use of minimum residual disease (MRD) as a surrogate endpoint for hematologic malignancies. Read More
